Clinical trial
CPG 7909 Injection in Non-Small Cell Lung Cancer
NCT00070629 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00070629 |
|---|---|
| Title | CPG 7909 Injection in Non-Small Cell Lung Cancer |
| Official title | Promune™ (CPG 7909 Injection) In Combination With Chemotherapy In Patients With Advanced Or Metastatic Non-Small Cell Lung Cancer, A Randomized, Multi-Center, Controlled, Phase 2 Study |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma, Non-Small Cell Lung |
| Intervention type | Drug |
| Interventions | CPG 7909, Chemotherapy |
| Enrollment | 116 |
| Start date | May 1, 2003 |
| Completion | Jul 1, 2007 |
| First posted | Oct 8, 2003 |
| Last update posted | Feb 10, 2009 |
| Countries | Canada, Germany, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: